Share Purchase Warrants (Tables)
|
12 Months Ended |
Jan. 31, 2026 |
|---|
| Share Purchase Warrants |
|
| Schedule of continuity of liability-classified warrants |
| | Number of Warrants | | | Weighted Average Exercise Price US$ | | | Weighted Average Remaining Contractual Life (Years) | | | Liability Amount $ | | Balance, January 31, 2023 | | | – | | | | – | | | | – | | | | – | | Granted (Note 9(h)) | | | 3,571,429 | | | | 0.11 | | | | 5.00 | | | | 48,846 | | Change in fair value | | | – | | | | – | | | | – | | | | 176,247 | | Balance, January 31, 2024 | | | 3,571,429 | | | | 0.11 | | | | 4.12 | | | | 225,093 | | Change in fair value | | | – | | | | – | | | | – | | | | 79,345 | | Balance, January 31, 2025 | | | 3,571,429 | | | | 0.11 | | | | 3.12 | | | | 304,438 | | Change in fair value | | | – | | | | – | | | | – | | | | (189,425 | ) | Balance, January 31, 2026 | | | 3,571,429 | | | | 0.11 | | | | 2.12 | | | | 115,013 | |
|
| Schedule of liability-classified warrants were outstanding |
Number of Warrants | | | Exercise Price US$ | | | Expiry Date | | 3,571,429 | | | 0.11 | | | March 14, 2028 | |
|
| Schedule of assumption used for fair values of warrant liabilities |
| | | January 31, 2026 | | | | January 31, 2025 | | Risk free interest rates | | | 2.56% | | | | 2.64% | | Volatilities | | | 121% | | | | 114% | | Fair values of common shares | | | US$0.038 | | | | US$0.089 | | Expected dividends | | | Nil% | | | | Nil% | | Expected lives | | | 2.12 years | | | | 3.12 years | | Exercise prices | | | US$0.11 | | | | US$US$0.11 | | Fair values of warrants | | | US$0.02 | | | | US$0.06 | |
|
| Schedule of continuity of liability-classified warrants of MedMelior |
| | Number of Warrants | | | Weighted Average Exercise Price US$ | | | Weighted Average Remaining Contractual Life (Years) | | | Liability Amount $ | | Balance, January 31, 2023 | | | 96,667 | | | | 1.25 | | | | 1.36 | | | | 20,700 | | Granted (Note 12) | | | 221,333 | | | | 1.25 | | | | 2.00 | | | | 72,190 | | Change in fair value | | | – | | | | – | | | | – | | | | (38,483 | ) | Balance, January 31, 2024 | | | 318,000 | | | | 1.25 | | | | 1.02 | | | | 54,407 | | Expired | | | (96,667 | ) | | | (1.25 | ) | | | – | | | | – | | Change in fair value | | | – | | | | – | | | | – | | | | (45,909 | ) | Balance, January 31, 2025 | | | 221,333 | | | | 1.25 | | | | 0.31 | | | | 8,498 | | Expired | | | (221,333 | ) | | | (1.25 | ) | | | – | | | | – | | Change in fair value | | | – | | | | – | | | | – | | | | (8,498 | ) | Balance, January 31, 2026 | | | – | | | | – | | | | – | | | | – | |
|
| Schedule of assumption used for fair values of MedMelior warrant liabilities |
| | | January 31, 2025 | | Risk free interest rates | | | 2.89% | | Volatilities | | | 101% | | Fair values of common shares | | | US$0.63 | | Expected dividends | | | Nil% | | Expected lives | | | 0.31 years | | Exercise prices | | | US$1.25 | | Fair values of warrants | | | US$0.03 | |
|
| Schedule of continuity of equity-classified warrants |
| | Number of Warrants | | | Weighted Average Exercise Price $ | | | Weighted Average Remaining Contractual Life (years) | | | | | | | | | | | | Balance, January 31, 2023 | | | 30,140,643 | | | | 0.52 | | | | 1.21 | | Granted (Notes 8(k), 8(m), 8(n) and 8(o)) | | | 23,104,000 | | | | 0.14 | | | | 4.24 | | Expired | | | (438,095 | ) | | | (0.70 | ) | | | – | | | | | | | | | | | | | | | Balance, January 31, 2024 | | | 52,806,548 | | | | 0.35 | | | | 1.90 | | Granted (Notes 5(b), 5(c), 5(d), 5(f), 8(f), 8(g) and 8(h)) | | | 14,001,041 | | | | 0.12 | | | | 1.93 | | Expired | | | (23,316,250 | ) | | | (0.50 | ) | | | – | | | | | | | | | | | | | | | Balance, January 31, 2025 | | | 43,491,339 | | | | 0.20 | | | | 1.89 | | Granted (Notes 5(a), 5(c), 5(d) and 8(a)) | | | 7,073,987 | | | | 0.10 | | | | 1.33 | | Expired | | | (12,385,573 | ) | | | (0.36 | ) | | | – | | Exercised | | | (250,000 | ) | | | (0.10 | ) | | | – | | | | | | | | | | | | | | | Balance, January 31, 2026 | | | 37,929,753 | | | | 0.13 | | | | 1.28 | |
|
| Schedule of equity-classified warrants were outstanding |
Number of Warrants | | | Exercise Price $ | | | Expiry Date | | | | | | | | | | | 78,000 | | | | 0.10 | | | February 28, 2026 | | | 168,000 | | | | 0.10 | | | March 27, 2026 | | | 36,000 | | | | 0.10 | | | April 29, 2026 | | | 5,300,000 | | | | 0.13 | | | June 13, 2026 | | | 1,750,000 | | | | 0.13 | | | July 1, 2026 | | | 2,950,000 | | | | 0.10 | | | August 30, 2026 | | | 350,000 | | | | 0.10 | | | August 31, 2026 | | | 5,706,849 | | | | 0.10 | | | September 27, 2026 | | | 4,090,904 | | | | 0.10 | | | October 1, 2026 | | | 300,000 | | | | 0.10 | | | October 29, 2026 | | | 15,000,000 | | | | 0.15 | | | March 14, 2028 | | | 2,200,000 | | | | 0.15 | | | July 9, 2028 | | | 37,929,753 | | | | | | | |
|
| Schedule of assumptions used for fair value of other equity-classified warrants issued |
| | January 31, 2025 | | | January 31, 2024 | | Nature of warrants | | Brokers’ warrants (Notes 5(b), 5(c) and 5(e)) | | | Brokers’ warrants (Notes 7(k) and 7(n)) | | Dates of grant | | February 29, March 28 and April 30, 2024 | | | March 14 and August 31, 2023 | | Risk free interest rates | | 4.13% to 4.33% | | | 3.72% and 4.64% | | Volatilities | | 114% to 115% | | | 114% and 112% | | Fair values of common shares on grant dates | | $0.085 to $0.10 | | | $0.085 | | Expected dividends | | Nil% | | | Nil% | | Expected lives | | Two (2) years | | | Two (2) years | | Exercise prices | | $0.10 | | | $0.10 | | Fair values of warrants on grant dates | | $0.05 to $0.06 | | | $0.05 | |
|